AstraZeneca (LSE:AZN) recently experienced a weekly price move of 2% amid announcements that could have supported its ...

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...

AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

AstraZeneca's baxdrostat demonstrated significant blood pressure reduction in a late-stage trial for treatment-resistant ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

AstraZeneca's new drug, baxdrostat, has successfully lowered blood pressure in a late-stage trial for treatment-resistant ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...